Tristel plc (TSNLF) Q2 2026 Earnings Call Transcript

Operator

Good morning, and welcome to the Tristel plc Interim Results Investor Presentation. [Operator Instructions]

Before we begin, I would like to submit the following poll. And I would now like to hand you over to the management team of Tristel. Matt, good morning to you.

Matthew Sassone
CEO & Director

Hi. Good morning. Thank you for joining us today for Tristel’s interim results H1 financial year 2026. I’m joined today by Anna Wasyl, Tristel’s CFO; and Julija Shabanova, who is Tristel’s Executive Director.

I appreciate that Julija may be a new name to some of the investors that are joining us today. So let me just give a brief background into her. She’s been Executive Director at Tristel and President of our U.S. subsidiary. This year actually marks her 20th year with Tristel. So she’s a very long-serving member of the team. Julija has really been an instrumental part of the leadership team. She executed the scientific program with the FDA, securing our U.S. market entry and really has been leading our commercial efforts with working on the launch of our 2 key products there, Ultrasound and OPH. As we go through the presentation, Julija will be updating you all on the progress we’re making in the U.S.A.

So that being said, let me just also take a moment to acknowledge the announcement that was made earlier this year that I will be stepping down as Chief Executive at the end of the financial year. This was a deeply considered personal decision. Tristel is a business with exceptional people, a strong depth in its leadership and a very clear strategic outlook and